It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,

A mother-of-two was diagnosed with breast cancer after an agonising 18-month wait for a preventative operation. Sharni Marks, discovered she carried the BRCA2 gene in 2018. This significantly increases the risk of developing breast cancer if it alters but surgery to remove both breasts can cut chance by 90%.

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — including colorectal, gastric, kidney and liver cancer — is also on the rise, though cancer among patients under 50 is still relatively rare overall, Dr. Partridge said.

The Pfizer Foundation has provided $15 million investment to a three-year initiative to improve the lives of women with breast cancer in Rwanda, Ghana, and Tanzania.

Morgan Pressel's 18th annual Morgan & Friends event raised a record $1,022,000 to support the fight against breast cancer. Pressel, 36, lost her mother Kathy to breast cancer in 2003, and her memory is at the heart of the mission.

Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.

Technology could soon do more than assist doctors. Thanks to advancements in cancer-identifying AI, it could actively save lives. A new study recently showcased how AI can revolutionize breast cancer detection, improving accuracy and easing radiologists’ workload.

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.7% earlier. Over the past three years, the stock posted a daily gain of more than 8% only four times.

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves patient outcomes.

Artificial Intelligence can improve breast cancer detection and reduce workload on physicians, according to a new study from Germany featuring over 461,000 women.